Gritstone Bio Inc (NAS:GRTS)
$ 0.8179 0.0305 (3.87%) Market Cap: 88.80 Mil Enterprise Value: 142.47 Mil PE Ratio: 0 PB Ratio: 5.84 GF Score: 30/100

Gritstone Oncology Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 04:00PM GMT
Release Date Price: $10.75 (-4.87%)
Shelby Barada;JPMorgan;Investment Banking Associate

Good morning, everyone. I'm Shelby Barada with JPMorgan's Healthcare Investment Banking team. I'm very pleased to be here with Dr. Andrew Allen, President and Co-Founder and CEO of Gritstone Oncology. The breakout following this will be held immediately following the presentation in the Olympic room. And with that, over to Andrew.

Andrew R. Allen
Gritstone Oncology, Inc. - Co-Founder, President, CEO & Director

Thanks, Shelby. Good morning, everybody. Indeed, I'm Andrew Allen, I'm one of the Co-founders, the CEO of Gritstone Oncology. We're a public company. We went public in September of 2018, and I'll be making some forward-looking statements.

Gritstone Oncology is now 4.5 years old. We have around 170 employees. And we're a company that began life focused on deliver antigen-based immunotherapies to cancer patients. We now have 2 neoantigen-based immunotherapies in Phase I clinical trials. And I will show you a little data from those trials today.

If you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot